Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity – Enrollment and dosing of patients commenced in rilonacept pivotal Phase 3 trial – Enrollment and dosing of patients commenced in mavrilimumab global Phase 2 trial – KPL-716 advancing into two...